Hematology & Hematologic Malignancies Publications

Hematology Faculty Publications FY23

JULY

  1. Kanack AJ, Bayas A, George G, Abou-Ismail MY, Singh B, Kohlhagen MC, Splinter NP, Christ M, Naumann M, Moser KA, Smock KJ, Grazioli A, Wen R, Wang D, Murray DL, Padmanabhan A. Monoclonal and oligoclonal anti-platelet factor 4 antibodies mediate VITT. Blood. 2022 Jul 7;140(1):73-77. doi: 10.1182/blood.2021014588. PMID: 35560046. PMCID: PMC9262283.

 

  1. Gociman S, Baron K, Hu B, Zussman J, Madigan LM. Blistering Lesions Associated With Loncastuximab Tesirine. JAMA Dermatol. 2022 Jul 1;158(7):831-832. doi: 10.1001/jamadermatol.2022.1389. PMID: 35583892.

 

  1. Clark NE, Katolik A, Taggart AJ, Buerer L, Holloway SP, Miller N, Phillips JD, Farrell CP, Damha MJ, Fairbrother WG. Metal content and kinetic properties of yeast RNA lariat debranching enzyme Dbr1. RNA.2022 Jul;28(7):927-936. doi: 10.1261/rna.079159.122. PMID: 35459748. PMCID: PMC9202583.

 

  1. Steinbach M, Julian K, McClune B, Sborov DW. Toxicity management strategies for next-generation novel therapeutics in multiple myeloma. Ther Adv Hematol. 2022 Jul 15;13:20406207221100659. doi: 10.1177/20406207221100659. PMID: 35860442. PMCID: PMC9289924.

 

  1. Hamid MS, Rutherford SC, Jang H, Kim S, Patel K, Bartlett NL, Malecek MK, Watkins MP, Maddocks KJ, Bond DA, Feldman TA, Magarelli G, Advani RH, Spinner MA, Evens AM, Shah M, Ahmed S, Stephens DM, Allen P, Tees MT, Karmali R, Cheson BD, Yazdy MS, Strouse C, Bailey NA, Pagel JM, Ramchandren R. Outcomes Among Classical Hodgkin Lymphoma Patients After an Interim PET Scan: A Real-World Experience. Clin Lymphoma Myeloma Leuk. 2022 Jul;22(7):e435-e442. doi: 10.1016/j.clml.2021.12.012. PMID: 35093285.

 

  1. Black GS, Huang X, Qiao Y, Tarapcsak S, Rogers KA, Misra S, Byrd JC, Marth GT, Stephens DM, Woyach JA. Subclonal evolution of CLL driver mutations is associated with relapse in ibrutinib- and acalabrutinib-treated patients. Blood. 2022 Jul 28;140(4):401-405. doi: 10.1182/blood.2021015132. PMID: 35476648. PMCID: PMC9335504.

 

  1. Friedman DR, Halwani AS, Kelley MJ. Reply to B.L. King-Kallimanis et al. JCO Clin Cancer Inform. 2022 Jul;6:e2200075. doi: 10.1200/CCI.22.00075. PMID: 35878070.

 

  1. Shah H, Kim S, Klimecki S, Charlson K, Uberti J, Schiffer CA, Fiala MA, Seymour E. Racial disparities in time to hematopoietic cell transplant among patients with hematologic malignancies at a large urban academic center. Bone Marrow Transplant. 2022 Jul;57(7):1213-1215. doi: 10.1038/s41409-022-01706-6. PMID: 35581406. PMCID: PMC9665109.

 

  1. Himbert C, Hathaway CA, Daniels B, Salas K, Ashworth A, Gigic B, Lin T, Viskochil R, Kirchhoff AC, Grossman D, Ose J, Tward J, Scaife C, Figueiredo JC, Toriola AT, Beck A, Shibata D, Gonzalez BD, Matsen C, Christenson C, Ma DS, Colman H, Hunt JP, Jones KB, Lee CJ, Larson M, Onega T, Akerley WL, Li CI, Schneider M, Penedo FJ, Siegel EM, Tworoger SS, Ulrich CM, Peoples AR. Factors associated with changes in exercise behaviors during the COVID-19 pandemic. Cancer Causes Control. 2022 Jul;33(7):939-950. doi: 10.1007/s10552-022-01580-z. PMID: 35554777; PMCID: PMC9096745.

 

 

 

AUGUST

 

  1. Burningham Z, Lagha RR, Duford-Hutchinson B, Callaway-Lane C, Sauer BC, Halwani AS, Bell J, Huynh T, Douglas JR, Kramer BJ. Developing the VA Geriatric Scholars Programs' Clinical Dashboards Using the PDSA Framework for Quality Improvement. Appl Clin Inform. 2022 Aug;13(4):961-970. doi: 10.1055/s-0042-1757553. PMID: 36223868. PMCID: PMC9556171.

 

  1. Fang MC, Go AS, Prasad PA, Zhou HX, Parks AL, Fan D, Portugal C, Sung SH, Reynolds K. Health-related quality of life associated with warfarin and direct oral anticoagulants in venous thromboembolism. Thromb Res. 2022 Aug;216:97-102. doi: 10.1016/j.thromres.2022.06.008. PMID: 35779378.

 

  1. Stephens DM, Huang Y, Ruppert AS, Walker JS, Canfield D, Cempre CB, Fu Q, Baker S, Hu B, Shah H, Vadeboncoeur R, Rogers KA, Bhat S, Jaglowski SM, Lockman H, Lapalombella R, Byrd JC, Woyach JA. Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I Study. Clin Cancer Res. 2022 Aug 2;28(15):3242-3247. doi: 10.1158/1078-0432.CCR-21-3867. PMID: 35608822. PMCID: PMC9364840.

 

  1. Rock CB, Chipman JJ, Parsons MW, Weil CR, Hutten RJ, Tao R, Tward JD, Shah HR, Hu B, Stephens DM, Gaffney DK. Second Primary Malignancies in Diffuse Large B-cell Lymphoma Survivors with 40 Years of Follow Up: Influence of Chemotherapy and Radiation Therapy. Adv Radiat Oncol. 2022 Jul 26;7(6):101035. doi: 10.1016/j.adro.2022.101035. PMID: 36420188. PMCID: PMC9677201.

 

  1. Fatoki RA, Koehn K, Kelkar A, Al Hadidi S, Mehra N, Mian H, Landgren O, Kazandjian D, Hoffman J, Sborov DW, Mohyuddin GR. Global Myeloma Trial Participation and Drug Access in the Era of Novel Therapies. JCO Glob Oncol. 2022 Aug;8:e2200119. doi: 10.1200/GO.22.00119. PMID: 35960904. PMCID: PMC9470137.

 

  1. Kanack AJ, Jones C, Singh B, Leger R, Splinter N, Heikal NM, Pruthi RK, Chen D, George G, Abou-Ismail MY, Wool GD, Gundabolu K, Padmanabhan A. Off-the-shelf cryopreserved platelets for the detection of HIT and VITT antibodies. Blood. 2022 Aug 23:blood.2022017283. doi: 10.1182/blood.2022017283. PMID: 35998675.

 

  1. Hoshina Y, Galli J, Wong KH, Kovacsovics T, Steinbach M, Salzman KL, McNally JS, Lancaster E, Paz Soldán MM, Clardy SL. GABA-A Receptor Encephalitis After Autologous Hematopoietic Stem Cell Transplant forMultiple Myeloma: Three Cases and Literature Review. Neurol Neuroimmunol Neuroinflamm. 2022 Aug 26;9(6):e200024. doi: 10.1212/NXI.0000000000200024. PMID: 36028311; PMCID: PMC9417160.

 

  1. Li P, Brown S, Williams M, White T, Xie W, Cui W, Peker D, Lei L, Kunder CA, Wang HY, Murray SS, Vagher J, Kovacsovics T, Patel JL. The genetic landscape of germline DDX41 variants predisposing to myeloid neoplasms. Blood. 2022 Aug 18;140(7):716-755. doi: 10.1182/blood.2021015135. PMID: 35671390; PMCID: PMC9389629.

 

  1. Sekeres MA, Schuster M, Joris M, Krauter J, Maertens J, Breems D, Gyan E, Kovacsovics T, Verma A, Vyas P, Wang ES, Ching K, O'Brien T, Gallo Stampino C, Ma WW, Kudla A, Chan G, Zeidan AM. A phase 1b study of glasdegib + azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes. Ann Hematol. 2022 Aug;101(8):1689-1701. doi: 10.1007/s00277-022-04853-4. PMID: 35488900.

 

 

 

SEPTEMBER

 

  1. Abou-Ismail, Kanack AJ, Splinter NP, Smock KJ, Moser KA, Padmanabhan, A. Safety of BNT162b2 mRNA vaccine booster in the setting of Ad26.COV2.S-associated VITT. Blood Adv. 2022  Sep 27;6(18):5327-5329. doi: 10.1182/bloodadvances.2022007753. PMID: 35468623. PMCID: PMC9631692.

 

  1. Rodgers GM, Ward JH, Bray PF. 80 years of Clinical Hematology. Br J Haematol. 2022 Sep;198(5):802. doi: 10.1111/bjh.18346. PMID: 35802037.

 

  1. Grootes I, Keeman R, Blows FM, Milne RL, Giles GG, Swerdlow AJ, Fasching PA, Abubakar M, Andrulis IL, Anton-Culver H, Beckmann MW, Blomqvist C, Bojesen SE, Bolla MK, Bonanni B, Briceno I, Burwinkel B, Camp NJ, Castelao JE, Choi JY, Clarke CL, Couch FJ, Cox A, Cross SS, Czene K, Devilee P, Dörk T, Dunning AM, Dwek M, Easton DF, Eccles DM, Eriksson M, Ernst K, Evans DG, Figueroa JD, Fink V, Floris G, Fox S, Gabrielson M, Gago-Dominguez M, García-Sáenz JA, González-Neira A, Haeberle L, Haiman CA, Hall P, Hamann U, Harkness EF, Hartman M, Hein A, Hooning MJ, Hou MF, Howell SJ; ABCTB Investigators; kConFab Investigators, Ito H, Jakubowska A, Janni W, John EM, Jung A, Kang D, Kristensen VN, Kwong A, Lambrechts D, Li J, Lubiński J, Manoochehri M, Margolin S, Matsuo K, Taib NAM, Mulligan AM, Nevanlinna H, Newman WG, Offit K, Osorio A, Park SK, Park-Simon TW, Patel AV, Presneau N, Pylkäs K, Rack B, Radice P, Rennert G, Romero A, Saloustros E, Sawyer EJ, Schneeweiss A, Schochter F, Schoemaker MJ, Shen CY, Shibli R, Sinn P, Tapper WJ, Tawfiq E, Teo SH, Teras LR, Torres D, Vachon CM, van Deurzen CHM, Wendt C, Williams JA, Winqvist R, Elwood M, Schmidt MK, García-Closas M, Pharoah PDP. Incorporating progesterone receptor expression into the PREDICT breast prognostic model. Eur J Cancer. 2022 Sep;173:178-193. doi: 10.1016/j.ejca.2022.06.011. PMID: 35933885.

 

  1. Macauda A, Clay-Gilmour A, Hielscher T, Hildebrandt MAT, Kruszewski M, Orlowski RZ, Kumar SK, Ziv E, Orciuolo E, Brown EE, Försti A, Waller RG, Machiela MJ, Chanock SJ, Camp NJ, Rymko M, Raźny M, Cozen W, Várkonyi J, Piredda C, Pelosini M, Belachew AA, Subocz E, Hemminki K, Rybicka-Ramos M, Giles GG, Milne RL, Hofmann JN, Zaucha JM, Vangsted AJ, Goldschmidt H, Rajkumar SV, Tomczak W, Sainz J, Butrym A, Watek M, Iskierka-Jazdzewska E, Buda G, Robinson DP, Jurczyszyn A, Dudziński M, Martinez-Lopez J, Sinnwell JP, Slager SL, Jamroziak K, Reis RMV, Weinhold N, Bhatti P, Carvajal-Carmona LG, Zawirska D, Norman AD, Mazur G, Berndt SI, Campa D, Vachon CM, Canzian F. Does a Multiple Myeloma Polygenic Risk Score Predict Overall Survival of Patients with Myeloma? Cancer Epidemiol Biomarkers Prev. 2022 Sep 2;31(9):1863-1866. doi: 10.1158/1055-9965.EPI-22-0043. PMID: 35700034.

 

  1. Yu B, Osman AEG, Sladojevic N, Prabhu N, Tai HC, Chen D, Perla G, Park L, Larson RA, Liao JK. Involvement of Rho-Associated Coiled-Coil Containing Kinase (ROCK) in BCR-ABL1 Tyrosine Kinase Inhibitor Cardiovascular Toxicity. JACC CardioOncol. 2022 Sep 20;4(3):371-383. doi: 10.1016/j.jaccao.2022.06.004. PMID: 36213346. PMCID: PMC9537085.

 

  1. Zhang Y, Godara A, Pan S, Toskic D, Mann H, Sborov D, Comenzo R, Kansagra A. Belantamab mafodotin in patients with relapsed/refractory AL amyloidosis with myeloma. Ann Hematol. 2022 Sep;101(9):2119-2121. doi: 10.1007/s00277-022-04890-z. PMID: 35821344.

 

  1. Chaturvedi S, Antun AG, Farland AM, Woods R, Metjian A, Park YA, de Ridder G, Gibson B, Kasthuri RS, Liles DK, Akwaa F, Clover T, Baumann Kreuziger L, Sadler JE, Sridharan M, Go RS, McCrae KR, Upreti HV, Liu A, Lim MY, Gangaraju R, Zheng XL, Raval JS, Masias C, Cataland SR, Johnson A, Davis E, Evans MD, Mazepa MA; United States Thrombotic Microangiopathies Consortium. Race, rituximab, and relapse in TTP. Blood. 2022 Sep 22;140(12):1335-1344. doi: 10.1182/blood.2022016640. PMID: 35797471. PMCID: PMC9710186.

 

  1. Tantravahi SK, Huber BD, Vagher J, Maese L, Pomicter AD, Al-Sweel N, Asch JD, Toydemir RM, Hong B, Parker C. Genome-wide uniparental disomy as a mechanism of immune escape in acquired aplastic anaemia. Br J Haematol. 2022 Sep;198(6):e78-e81. doi: 10.1111/bjh.18351. PMID: 35876645.

 

  1. Mohyuddin GR, Mehra N, Ryll B, Prasad V. Control participants of randomised trials: an often forgotten, vulnerable population. Lancet Haematol. 2022 Sep;9(9):e634-e636. doi: 10.1016/S2352-3026(22)00254-X. PMID: 36055323.

 

  1. Ventura P, Sardh E, Longo N, Balwani M, Plutzky J, Gouya L, Phillips J, Rhyee S, Fanelli MJ, Sweetser MT, Petrides PE. Hyperhomocysteinemia in acute hepatic porphyria (AHP) and implications for treatment with givosiran. Expert Rev Gastroenterol Hepatol. 2022 Sep;16(9):879-894. doi: 10.1080/17474124.2022.2110469. PMID: 35929959.

 

  1. Zhai Y, Dong S, Li H, Zhang Y, Shami P, Chen M. Antibody-mediated depletion of programmed death 1-positive (PD-1+) cells. J Control Release. 2022 Sep;349:425-433. doi: 10.1016/j.jconrel.2022.07.010. PMID: 35820540.

 

  1. Peoples AR, Oswald LB, Ose J, Daniels B, Himbert C, Hathaway CA, Gigic B, Kirchhoff AC, Lin T, Grossman D, Tward J, Varghese TK Jr, Figueiredo JC, Toriola AT, Beck A, Scaife C, Shibata D, LaStayo P, Gonzalez B, Salas K, Ashworth A, Matsen C, Christenson C, Ma DS, Colman H, Hunt JP, Jones KB, Lee CJ, Larson M, Onega T, Akerley WL, Li CI, Schneider M, Penedo FJ, Siegel EM, Tworoger SS, Ulrich CM. Impact of the COVID-19 pandemic on rural and urban cancer patients' experiences, health behaviors, and perceptions. J Rural Health. 2022 Sep;38(4):886-899. doi: 10.1111/jrh.12648. PMID: 35243690; PMCID: PMC9115146.

 

OCTOBER

 

  1. Wittorf KJ, Weber KK, Swenson SA, Buckley SM. Ubiquitin E3 ligase FBXO21 regulates cytokine-mediated signaling pathways, but is dispensable for steady-state hematopoiesis. Exp Hematol. 2022 Oct;114:33-42.e3. doi: 10.1016/j.exphem.2022.08.002. PMID: 35987460.

 

  1. Dixon-Suen SC, Lewis SJ, Martin RM, English DR, Boyle T, Giles GG, Michailidou K, Bolla MK, Wang Q, Dennis J, Lush M, Investigators A, Ahearn TU, Ambrosone CB, Andrulis IL, Anton-Culver H, Arndt V, Aronson KJ, Augustinsson A, Auvinen P, Beane Freeman LE, Becher H, Beckmann MW, Behrens S, Bermisheva M, Blomqvist C, Bogdanova NV, Bojesen SE, Bonanni B, Brenner H, Brüning T, Buys SS, Camp NJ, Campa D, Canzian F, Castelao JE, Cessna MH, Chang-Claude J, Chanock SJ, Clarke CL, Conroy DM, Couch FJ, Cox A, Cross SS, Czene K, Daly MB, Devilee P, Dörk T, Dwek M, Eccles DM, Eliassen AH, Engel C, Eriksson M, Evans DG, Fasching PA, Fletcher O, Flyger H, Fritschi L, Gabrielson M, Gago-Dominguez M, García-Closas M, García-Sáenz JA, Goldberg MS, Guénel P, Gündert M, Hahnen E, Haiman CA, Häberle L, Håkansson N, Hall P, Hamann U, Hart SN, Harvie M, Hillemanns P, Hollestelle A, Hooning MJ, Hoppe R, Hopper J, Howell A, Hunter DJ, Jakubowska A, Janni W, John EM, Jung A, Kaaks R, Keeman R, Kitahara CM, Koutros S, Kraft P, Kristensen VN, Kubelka-Sabit K, Kurian AW, Lacey JV, Lambrechts D, Le Marchand L, Lindblom A, Loibl S, Lubiński J, Mannermaa A, Manoochehri M, Margolin S, Martinez ME, Mavroudis D, Menon U, Mulligan AM, Murphy RA, Collaborators N, Nevanlinna H, Nevelsteen I, Newman WG, Offit K, Olshan AF, Olsson H, Orr N, Patel A, Peto J, Plaseska-Karanfilska D, Presneau N, Rack B, Radice P, Rees-Punia E, Rennert G, Rennert HS, Romero A, Saloustros E, Sandler DP, Schmidt MK, Schmutzler RK, Schwentner L, Scott C, Shah M, Shu XO, Simard J, Southey MC, Stone J, Surowy H, Swerdlow AJ, Tamimi RM, Tapper WJ, Taylor JA, Terry MB, Tollenaar RAEM, Troester MA, Truong T, Untch M, Vachon CM, Joseph V, Wappenschmidt B, Weinberg CR, Wolk A, Yannoukakos D, Zheng W, Ziogas A, Dunning AM, Pharoah PDP, Easton DF, Milne RL, Lynch BM. Physical activity, sedentary time and breast cancer risk: a Mendelian randomisation study. Br J Sports Med. 2022 Oct;56(20):1157-1170. doi: 10.1136/bjsports-2021-105132. PMID: 36328784.

 

  1. Giardiello D, Hooning MJ, Hauptmann M, Keeman R, Heemskerk-Gerritsen BAM, Becher H, Blomqvist C, Bojesen SE, Bolla MK, Camp NJ, Czene K, Devilee P, Eccles DM, Fasching PA, Figueroa JD, Flyger H, García-Closas M, Haiman CA, Hamann U, Hopper JL, Jakubowska A, Leeuwen FE, Lindblom A, Lubiński J, Margolin S, Martinez ME, Nevanlinna H, Nevelsteen I, Pelders S, Pharoah PDP, Siesling S, Southey MC, van der Hout AH, van Hest LP, Chang-Claude J, Hall P, Easton DF, Steyerberg EW, Schmidt MK. PredictCBC-2.0: a contralateral breast cancer risk prediction model developed and validated in ~ 200,000 patients. Breast Cancer Res. 2022 Oct 21;24(1):69. doi: 10.1186/s13058-022-01567-3. PMID: 36271417. PMCID: PMC9585761.

 

  1. Lee CJ, Wang T, Chen K, Arora M, Brazauskas R, Spellman SR, Kitko C, MacMillan ML, Pidala JA, Auletta JJ, Badawy SM, Bhatt N, Bhatt VR, Cahn JY, DeFilipp Z, Diaz MA, Farhadfar N, Gadalla S, Gale RP, Hashem H, Hashmi S, Hematti P, Hong S, Hossain NM, Inamoto Y, Lekakis LJ, Modi D, Patel S, Sharma A, Solomon S, Couriel DR. Association of Chronic Graft-versus-Host Disease with Late Effects following Allogeneic Hematopoietic Cell Transplantation for Children with Hematologic Malignancy. Transplant Cell Ther. 2022 Oct;28(10):712.e1-712.e8. doi: 10.1016/j.jtct.2022.07.014. PMID: 35863740. PMCID: PMC9547959.

 

  1. Saliba RM, Alousi AM, Pidala J, Arora M, Spellman SR, Hemmer MT, Wang T, Abboud C, Ahmed S, Antin JH, Beitinjaneh A, Buchbinder D, Byrne M, Cahn JY, Choe H, Hanna R, Hematti P, Kamble RT, Kitko CL, Laughlin M, Lekakis L, MacMillan ML, Martino R, Mehta PA, Nishihori T, Patel SS, Perales MA, Rangarajan HG, Ringdén O, Rosenthal J, Savani BN, Schultz KR, Seo S, Teshima T, van der Poel M, Verdonck LF, Weisdorf D, Wirk B, Yared JA, Schriber J, Champlin RE, Ciurea SO. Characteristics of Graft-Versus-Host Disease (GvHD) After Post-Transplantation Cyclophosphamide Versus Conventional GvHD Prophylaxis.Transplant Cell Ther. 2022 Oct;28(10):681-693. doi: 10.1016/j.jtct.2022.07.013. PMID: 35853610.

 

  1. Mohyuddin GR, Ahlstrom JM, Chmielewski CA, Sweeney NW, Molina TH, Cheung CS, Ballard EW, Seng FF, Van Oekelen O, Godara A, McClune B, Sborov D. A survey on the patient perspective on cure in multiple myeloma. Lancet Haematol. 2022 Oct;9(10):e716-e719. doi: 10.1016/S2352-3026(22)00264-2. PMID: 36174636.

 

  1. Tommy Gambles M, Li J, Christopher Radford D, Sborov D, Shami P, Yang J, Kopeček J. Simultaneous crosslinking of CD20 and CD38 receptors by drug-free macromolecular therapeutics enhances B cell apoptosis in vitro and in vivo. J Control Release. 2022 Oct;350:584-599. doi: 10.1016/j.jconrel.2022.08.045. PMID: 36037975. PMCID: PMC9561060.

 

  1. Parsons MW, Wada DA, Halwani AS, Tao R, Gaffney DK. Improved overall survival over time in advanced stage mycosis fungoides: a cross-sectional study. Leuk Lymphoma. 2022 Oct;63(10):2428-2435. doi: 10.1080/10428194.2022.2081322. PMID: 35749643.

 

  1. Green YS, Ferreira Dos Santos MC, Fuja DG, Reichert EC, Campos AR, Cowman SJ, Acuña Pilarte K, Kohan J, Tripp SR, Leibold EA, Sirohi D, Agarwal N, Liu X, Koh MY. ISCA2 inhibition decreases HIF and induces ferroptosis in clear cell renal carcinoma. Oncogene. 2022 Oct;41(42):4709-4723. doi: 10.1038/s41388-022-02460-1. PMID: 36097192. PMCID: PMC9568429.

 

  1. Bruno AM, Allshouse AA, Campbell HM, Branch DW, Lim MY, Silver RM, Metz TD. Weight-Based Compared With Fixed-Dose Enoxaparin Prophylaxis After Cesarean Delivery: A Randomized Controlled Trial. Obstet Gynecol. 2022 Oct 1;140(4):575-583. doi: 10.1097/AOG.0000000000004937. PMID: 36075079.

 

  1. Kralova B, Sochorcova L, Song J, Jahoda O, Hlusickova Kapralova K, Prchal JT, Divoky V, Horvathova M. Developmental changes in iron metabolism and erythropoiesis in mice with human gain-of-function erythropoietin receptor. Am J Hematol. 2022 Oct;97(10):1286-1299. doi: 10.1002/ajh.26658. PMID: 35815815.

 

  1. Mughal TI, Pemmaraju N, Bejar R, Gale RP, Bose P, Kiladjian JJ, Prchal J, Royston D, Pollyea D, Valent P, Brümmendorf TH, Skorski T, Patnaik M, Santini V, Fenaux P, Kucine N, Verstovsek S, Mesa R, Barbui T, Saglio G, Van Etten RA. Perspective: Pivotal translational hematology and therapeutic insights in chronic myeloid hematopoietic stem cell malignancies. Hematol Oncol. 2022 Oct;40(4):491-504. doi: 10.1002/hon.2987. PMID: 35368098.

 

  1. Roberts JC, von Drygalski A, Zhou JY, Rodgers GM, Ansteatt K, Tarantino MD. Five Challenging Cases of Hereditary Antithrombin Deficiency Characterized by Thrombosis or Complicated Pregnancy. J Blood Med.2022 Oct 21;13:611-618. doi: 10.2147/JBM.S365996. PMID: 36303565. PMCID: PMC9595055.

 

  1. Incze MA, Parks AL, Stern RJ. Teaching a Deeper Understanding of the Medical Literature. J Gen Intern Med. 2022 Oct 31:1–2. doi: 10.1007/s11606-022-07851-4. PMID: 36316623. PMCID: PMC9628583.

 

  1. Sorror ML, Gooley TA, Storer BE, Gerds AT, Sekeres MA, Medeiros BC, Wang ES, Shami PJ, Adekola KUA, Luger SM, Baer MR, Rizzieri DA, Wildes T, Koprivnikar J, Smith J, Garrison M, Kojouri K, Schuler TA, Leisenring WM, Onstad L, Becker PS, Lee SJ, Sandmaier BM, Appelbaum FR, Estey E, McCune S. An 8-year pragmatic observation evaluation of the benefits of allogeneic HCT in older and medically infirm AML patients. Blood. 2022 Oct 19:blood.2022016916. doi: 10.1182/blood.2022016916. PMID: 36260765.

 

  1. Verstovsek S, Mesa R, Mascarenhas J, Tashi T, Shih W, Sato T, Urbanski R, Zagrijtschuk O, Zimmerman C. MPN-546 A Single-Arm Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Ropeginterferon alfa-2b-njft (P1101) in North American Adults With Essential Thrombocythemia. Clin Lymphoma Myeloma Leuk. 2022 Oct;22 Suppl 2:S342-S343. doi: 10.1016/S2152-2650(22)01469-0. PMID: 36164018.

 

  1. Zhao Y, Tang J, Zhou H, Takahashi T, Nomura T, Dennis E, Halwani A. TCL-456 Real-World Use of Mogamulizumab among Patients With Mycosis Fungoides and Sézary Syndrome Before and During COVID-19 in the United States. Clin Lymphoma Myeloma Leuk. 2022 Oct;22 Suppl 2:S400. doi: 10.1016/S2152-2650(22)01580-4. PMID: 36164130.

 

  1. Boyiadzis M, Zhang MJ, Chen K, Abdel-Azim H, Abid MB, Aljurf M, Bacher U, Badar T, Badawy SM, Battiwalla M, Bejanyan N, Bhatt VR, Brown VI, Castillo P, Cerny J, Copelan EA, Craddock C, Dholaria B, Perez MAD, Ebens CL, Gale RP, Ganguly S, Gowda L, Grunwald MR, Hashmi S, Hildebrandt GC, Iqbal M, Jamy O, Kharfan-Dabaja MA, Khera N, Lazarus HM, Lin R, Modi D, Nathan S, Nishihori T, Patel SS, Pawarode A, Sharma A, Solh M, Wagner JL, Wang T, Williams KM, Winestone LE, Wirk B, Hourigan CS, Litzow M, Kebriaei P, de Lima M, Page K, Weisdorf DJ. Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113 AML patients.Leukemia. 2022 Oct 30. doi: 10.1038/s41375-022-01738-3. PMID: 36310182.

 

  1. Tao R, Chen Y, Kim S, Ocier K, Lloyd S, Poppe MM, Lee CJ, Glenn MJ, Smith KR, Fraser A, Deshmukh V, Newman MG, Snyder J, Rowe KG, Gaffney DK, Haaland B, Hashibe M. Mental health disorders are more common in patients with Hodgkin lymphoma and may negatively impact overall survival. Cancer. 2022 Oct 1;128(19):3564-3572. doi: 10.1002/cncr.34359. PMID: 35916651.

 

  1. Saliba AN, Kaufmann SH, Stein EM, Patel PA, Baer MR, Stock W, Deininger MW, Blum W, Schiller GJ, Olin RL, Litzow MR, Lin TL, Ball BJ, Boyiadzis M, Traer E, Odenike O, Arellano ML, Walker AR, Duong VH, Kovacsovics TJ, Collins RH, Shoben AB, Heerema NA, Foster MC, Peterson KL, Schneider PA, Martycz M, Gana T, Rosenberg L, Marcus S, Yocum AO, Chen TL, Stefanos M, Mims AS, Borate U, Burd A, Druker BJ, Levine RL, Byrd JC, Foran JM. Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates. Blood Adv. 2022 Oct 31:bloodadvances.2022008625. doi: 10.1182/bloodadvances.2022008625. PMID: 36315007.

 

NOVEMBER

 

  1. López DA, Apostol AC, Lebish EJ, Valencia CH, Romero-Mulero MC, Pavlovich PV, Hernandez GE, Forsberg EC, Cabezas-Wallscheid, Beaudin AE. Prenatal inflammation perturbs murine fetal hematopoietic development and causes persistent changes to postnatal immunity. Cell Rep. 2022 Nov 22;41(8):111677. doi: 10.1016/j.celrep.2022.111677. PMID: 36417858.

 

  1. Giardiello D, Hooning MJ, Hauptmann M, Keeman R, Heemskerk-Gerritsen BAM, Becher H, Blomqvist C, Bojesen SE, Bolla MK, Camp NJ, Czene K, Devilee P, Eccles DM, Fasching PA, Figueroa JD, Flyger H, García-Closas M, Haiman CA, Hamann U, Hopper JL, Jakubowska A, Leeuwen FE, Lindblom A, Lubiński J, Margolin S, Martinez ME, Nevanlinna H, Nevelsteen I, Pelders S, Pharoah PDP, Siesling S, Southey MC, van der Hout AH, van Hest LP, Chang-Claude J, Hall P, Easton DF, Steyerberg EW, Schmidt MK. Correction: PredictCBC-2.0: a contralateral breast cancer risk prediction model developed and validated in ~ 200,000 patients. Breast Cancer Res. 2022 Nov 22;24(1):82. doi: 10.1186/s13058-022-01579-z. PMID: 36419099. PMCID: PMC9682632.

 

  1. McInturf G, Younger K, Sanchez C, Walde C, Abdallah AO, Ahmed N, Shune L, Sborov DW, Godara A, McClune B, Sinclair CT, Mohyuddin GR. Palliative care utilization, transfusion burden, and end-of-life care for patients with multiple myeloma. Eur J Haematol. 2022 Nov;109(5):559-565. doi: 10.1111/ejh.13843. PMID: 36054450.

 

  1. Young A, Lim MY, Sanders J, Branch DW, Simonsen SE. Pregnancy and childbirth in women with bleeding disorders: A retrospective cohort study. Haemophilia. 2022 Nov 17. doi: 10.1111/hae.14688. PMID: 36395791.

 

  1. Balwani M, Naik H, Overbey JR, Bonkovsky HL, Bissell DM, Wang B, Phillips JD, Desnick RJ, Anderson KE. A pilot study of oral iron therapy in erythropoietic protoporphyria and X-linked protoporphyria. Mol Genet Metab Rep. 2022 Nov 14;33:100939. doi: 10.1016/j.ymgmr.2022.100939. PMID: 36406817. PMCID: PMC9672425.

 

  1. Sborov DW, Baljevic M, Reeves B, Laubach J, Efebera YA, Rodriguez C, Costa LJ, Chari A, Silbermann R, Holstein SA, Anderson LD Jr, Kaufman JL, Shah N, Pei H, Patel S, Cortoos A, Bartlett JB, Vermeulen J, Lin TS, Voorhees PM, Richardson PG. Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study. Br J Haematol. 2022 Nov;199(3):355-365. doi: 10.1111/bjh.18432. PMID: 36111391.

 

  1. Salem AE, Shah HR, Covington MF, Koppula BR, Fine GC, Wiggins RH, Hoffman JM, Morton KA. PET-CT in Clinical Adult Oncology: I. Hematologic Malignancies. Cancers (Basel). 2022 Nov 30;14(23):5941. doi: 10.3390/cancers14235941. PMID: 36497423. PMCID: PMC9738711.

 

  1. Pemmaraju N, Kantarjian HM, Sweet KL, Wang ES, Senapati J, Wilson NR, Konopleva MY, Frankel AE, Gupta V, Mesa RA, Ulrickson ML, Gorak E, Bhatia S, Budak-Alpdogan T, Mason JR, Garcia-Romero MT, Lopez-Santiago NC, Cesarman-Maus G, Vachhani P, Lee S, Bhatt VR, Blum W, Walter RB, Bixby D, Gojo I, Duvic M, Rampal RK, de Lima M, Foran JM, Fathi AT, Hall A, Jacoby MA, Lancet JE, Mannis GN, Stein AS, Mims AS, Rizzieri D, Olin RL, Perl AE, Schiller GJ, Shami PJ, Stone RM, Strickland S, Wieduwilt MJ, Daver NG, Ravandi F, Vasu S, Guzman ML, Roboz GJ, Khoury JD, Qazilbash MH, Aung P, Cuglievan B, Madanat YF, Kharfan-Dabaja MA, Pawlowska AB, Taylor J, Tallman MS, Dhakal P, Lane AA. North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: Position on Standards of Care and Areas of Need. Blood. 2022 Nov 18:blood.2022017865. doi: 10.1182/blood.2022017865. PMID: 36399715.

 

  1. Stephens DM, Li H, Constine LS, Fitzgerald TJ, Leonard JP, Kahl BS, Song JY, LeBlanc ML, Smith SM, Persky DO, Friedberg JW. Extranodal presentation in limited-stage diffuse large Bcell lymphoma as a prognostic marker in three SWOG trials S0014, S0313 and S1001. Haematologica. 2022 Nov 1;107(11):2732-2736. doi: 10.3324/haematol.2022.281004. PMID: 35833300. PMCID: PMC9614528.

 

  1. Chuah YY, Tashi T, Kuo CJ. An unexpected cause of Cullen's sign: rupture of hepatocellular carcinoma. Br J Hosp Med (Lond). 2022 Nov 2;83(11):1. doi: 10.12968/hmed.2022.0250. PMID: 36454065.

 

  1. Cliff ERS, Mian H, Mohyuddin GR. Teclistamab in Relapsed or Refractory Multiple Myeloma. N Engl J Med.2022 Nov 3;387(18):1721-1722. doi: 10.1056/NEJMc2211969. PMID: 36322860.

 

  1. Van Oekelen O, Birrer N, Wesson W, Galate VL, Cliff ERS, Goodman AM, Abdallah AO, Chakraborty R, Prasad V, Mohyuddin GR. Characteristics of measurable residual disease assessment in myeloma: a review of clinical trials from 2015-2020. Blood Cancer J. 2022 Nov 15;12(11):155. doi: 10.1038/s41408-022-00750-1. PMID: 36379917. PMCID: PMC9666639.

 

  1. Jonas BA, DiNardo C, Fracchiolla N, Pristupa A, Ishizawa K, Jin J, Konopleva M, Ofran Y, Montesinos P, Kovacsovics T, Jang JH, Kantarjian H, Duan Y, Potluri J, Werner M, Pratz KW. Use of CYP3Ai and impact on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine in the VIALE-A study. Am J Hematol. 2022 Nov;97(11):E422-E425. doi: 10.1002/ajh.26707. PMID: 36053878.

 

DECEMBER

 

  1. LIM MY, Abou-Ismail YM, Branch DW. Differentiating and Managing Rare Thrombotic Microangiopathies During Pregnancy and Postpartum. Obstet Gynecol. 2022 Dec 1; Online ahead of print. doi: 10.1097/AOG.0000000000005024. PMID: 36455925.

 

  1. Manne BK, Campbell RA, Bhatlekar S, Ajanel A, Denorme F, Portier I, Middleton EA, Tolley ND, Kosaka Y, Montenont E, Guo L, Rowley JW, Bray PF, Jacob SP, Fukanaga R, Proud CG, Weyrich AS, Rondina MT. MAPK-interacting kinase 1 (Mnk1) regulates platelet production, activation, and thrombosis. Blood. 2022 Dec 8;140(23):2477-2489. doi: 10.1182/blood.2022015568. PMID: 35930749.

 

  1. Berndt SI, Vijai J, Benavente Y, Camp NJ, Nieters A, Wang Z, Smedby KE, Kleinstern G, Hjalgrim H, Besson C, Skibola CF, Morton LM, Brooks-Wilson AR, Teras LR, Breeze C, Arias J, Adami HO, Albanes D, Anderson KC, Ansell SM, Bassig B, Becker N, Bhatti P, Birmann BM, Boffetta P, Bracci PM, Brennan P, Brown EE, Burdett L, Cannon-Albright LA, Chang ET, Chiu BCH, Chung CC, Clavel J, Cocco P, Colditz G, Conde L, Conti DV, Cox DG, Curtin K, Casabonne D, De Vivo I, Diver WR, Dogan A, Edlund CK, Foretova L, Fraumeni JF Jr, Gabbas A, Ghesquières H, Giles GG, Glaser S, Glenn M, Glimelius B, Gu J, Habermann TM, Haiman CA, Haioun C, Hofmann JN, Holford TR, Holly EA, Hutchinson A, Izhar A, Jackson RD, Jarrett RF, Kaaks R, Kane E, Kolonel LN, Kong Y, Kraft P, Kricker A, Lake A, Lan Q, Lawrence C, Li D, Liebow M, Link BK, Magnani C, Maynadie M, McKay J, Melbye M, Miligi L, Milne RL, Molina TJ, Monnereau A, Montalvan R, North KE, Novak AJ, Onel K, Purdue MP, Rand KA, Riboli E, Riby J, Roman E, Salles G, Sborov DW, Severson RK, Shanafelt TD, Smith MT, Smith A, Song KW, Song L, Southey MC, Spinelli JJ, Staines A, Stephens D, Sutherland HJ, Tkachuk K, Thompson CA, Tilly H, Tinker LF, Travis RC, Turner J, Vachon CM, Vajdic CM, Van Den Berg A, Van Den Berg DJ, Vermeulen RCH, Vineis P, Wang SS, Weiderpass E, Weiner GJ, Weinstein S, Doo NW, Ye Y, Yeager M, Yu K, Zeleniuch-Jacquotte A, Zhang Y, Zheng T, Ziv E, Sampson J, Chatterjee N, Offit K, Cozen W, Wu X, Cerhan JR, Chanock SJ, Slager SL, Rothman N. Distinct germline genetic susceptibility profiles identified for common non-Hodgkin lymphoma subtypes. Leukemia. 2022 Dec;36(12):2835-2844. doi: 10.1038/s41375-022-01711-0. PMID: 36273105.

 

  1. Montgomery HD, Agarwal AM, Lim MY. A case of azathioprine-induced aplastic anemia. Int J Lab Hematol.2022 Dec;44(6):1015-1016. doi: 10.1111/ijlh.13927. PMID: 35799500.

 

  1. Siddiqui NS, Klein A, Godara A, Buchsbaum RJ, Hughes MC. Predicting In-Hospital Mortality After Acute Myeloid Leukemia Therapy: Through Supervised Machine Learning Algorithms. JCO Clin Cancer Inform. 2022 Dec;6:e2200044. doi: 10.1200/CCI.22.00044. PMID: 36542824.

 

  1. Campbell RA, Manne BK, Banerjee M, Middleton EA, Ajanel A, Schwertz H, Denorme F, Stubben C, Montenont E, Saperstein S, Page L, Tolley ND, Lim DL, Brown SM, Grissom CK, Sborov DW, Krishnan A, Rondina MT. IFITM3 regulates fibrinogen endocytosis and platelet reactivity in nonviral sepsis. J Clin Invest. 2022 Dec 1;132(23):e153014. doi: 10.1172/JCI153014. PMID: 36194487. PMCID: PMC9711880.

 

  1. Chhabra S, Callander N, Watts NL, Costa LJ, Thapa B, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, Chari A, Silbermann R, Jr LDA, Bal S, Dhakal B, Nathwani N, Shah N, Medvedova E, Bumma N, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Schmidt T, Orlowski RZ, Shain KH, Cowan AJ, Dholaria B, Cornell RF, Jerkins JH, Pei H, Cortoos A, Patel S, Lin TS, Usmani SZ, Richardson PG, Voorhees PM. Stem cell mobilization yields with daratumumab and lenalidomide-containing quadruplet induction therapy in newly diagnosed multiple myeloma: findings from the MASTER and GRIFFIN trials.Transplant Cell Ther. 2022 Dec 6:S2666-6367(22)01802-4. doi: 10.1016/j.jtct.2022.11.029. PMID: 36494017.

 

  1. Etekal T, Koehn K, Sborov DW, McClune B, Prasad V, Haslam A, Berger K, Booth C, Al Hadidi S, Abdallah AO, Goodman A, Mohyuddin GR. Time-to-event surrogate end-points in multiple myeloma randomised trials from 2005 to 2019: A surrogacy analysis. Br J Haematol. 2022 Dec 10. doi: 10.1111/bjh.18568. PMID: 36495317.

 

  1. Ujjani CS, Gooley TA, Spurgeon SE, Stephens DM, Lai C, Broome CM, O'Brien SM, Zhu H, Laing KJ, Winter AM, Pongas G, Greninger AL, Koelle DM, Siddiqi T, Davids MS, Rogers KA, Danilov AV, Sperling AL, Tu B, Sorensen T, Launchbury KM, Burrow CJ, Quezada G, Hill JA, Shadman M, Thompson PA. Diminished Humoral and Cellular Responses to SARS-CoV-2 Vaccines in Patients with Chronic Lymphocytic Leukemia. Blood Adv. 2022 Dec 14:bloodadvances.2022009164. doi: 10.1182/bloodadvances.2022009164. PMID: 36516082.

 

  1. Mohyuddin GR, Sinnarajah A, Gayowsky A, Chan KKW, Seow H, Mian H. Quality of end-of-life care in multiple myeloma: A 13-year analysis of a population-based cohort in Ontario, Canada. Br J Haematol.2022 Dec;199(5):688-695. doi: 10.1111/bjh.18401. PMID: 35949180.

 

  1. Ouchveridze E, Berger K, Mohyuddin GR. Value in Myeloma Care: Myth or Reality. Curr Hematol Malig Rep. 2022 Dec;17(6):206-216. doi: 10.1007/s11899-022-00669-1. PMID: 36040675.

 

  1. Atieh T, Atrash S, Ahmed N, Mohan M, Cui W, Shune L, Hajjar S, Mahmoudjafari Z, Quick J, Wishna A, Riffel J, McGuirk J, Mohyuddin GR, Abdallah AO. Belantamab in Combination with Dexamethasone in Patients with Triple-class Relapsed/Refractory Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2022 Dec;22(12):912-919. doi: 10.1016/j.clml.2022.08.003. PMID: 36127271.

 

  1. Mohyuddin GR, Chakraborty R, Calip GS, Ascha MS, Wang X, Rubinstein SM, Tuchman S, Costa L, Haaland B, Giri S, Mian H, Fonseca R, Sborov D. Prognostic value of translocation 11;14 in patients with relapsed/refractory myeloma receiving anti-CD38 therapy. Blood Cancer J. 2022 Dec 16;12(12):168. doi: 10.1038/s41408-022-00769-4. PMID: 36526617. PMCID: PMC9758218.

 

  1. Rudnick S, Phillips J, Bonkovsky H; Porphyrias Consortium of the Rare Diseases Clinical Research Network. Hepatoerythropoietic Porphyria. 2013 Oct 31 [updated 2022 Dec 22]. In: Adam MP, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2023. PMID: 24175354.

 

JANUARY

 

  1. Dicanio M, Giaccherini M, Clay-Gilmour A, Macauda A, Sainz J, Machiela MJ, Rybicka-Ramos M, Norman AD, Tyczyńska A, Chanock SJ, Barington T, Kumar SK, Bhatti P, Cozen W, Brown EE, Suska A, Haastrup EK, Orlowski RZ, Dudziński M, Garcia-Sanz R, Kruszewski M, Martinez-Lopez J, Beider K, Iskierka-Jazdzewska E, Pelosini M, Berndt SI, Raźny M, Jamroziak K, Rajkumar SV, Jurczyszyn A, Vangsted AJ, Collado PG, Vogel U, Hofmann JN, Petrini M, Butrym A, Slager SL, Ziv E, Subocz E, Giles GG, Andersen NF, Mazur G, Watek M, Lesueur F, Hildebrandt MAT, Zawirska D, Ebbesen LH, Marques H, Gemignani F, Dumontet C, Várkonyi J, Buda G, Nagler A, Druzd-Sitek A, Wu X, Kadar K, Camp NJ, Grzasko N, Waller RG, Vachon C, Canzian F, Campa D. A pleiotropic variant in DNAJB4 is associated with multiple myeloma risk. Int J Cancer. 2023 Jan 15;152(2):239-248. doi: 10.1002/ijc.34278. PMID: 36082445.

 

  1. Vardell VA, Ermann DA, Tantravahi SK, Haaland B, McClune B, Godara A, Mohyuddin GR, Sborov DW. Impact of academic medical center access on outcomes in multiple myeloma. Am J Hematol. 2023 Jan;98(1):41-48. doi: 10.1002/ajh.26759. PMID: 36266759.

 

  1. Mei M, Pillai R, Kim S, Estrada-Merly N, Afkhami M, Yang L, Meng Z, Abid MB, Aljurf M, Bacher U, Beitinjaneh A, Bredeson C, Cahn JY, Cerny J, Copelan E, Cutler C, DeFilipp Z, Diaz Perez MA, Farhadfar N, Freytes CO, Gadalla SM, Ganguly S, Gale RP, Gergis U, Grunwald MR, Hamilton BK, Hashmi S, Hildebrandt GC, Lazarus HM, Litzow M, Munker R, Murthy HS, Nathan S, Nishihori T, Patel SS, Rizzieri D, Seo S, Shah MV, Solh M, Verdonck LF, Vij R, Sobecks RM, Oran B, Scott BL, Saber W, Nakamura R. The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Transplantation Research (CIBMTR) analysis.Haematologica. 2023 Jan 1;108(1):150-160. doi: 10.3324/haematol.2021.280203. PMID: 35443559; PMCID: PMC9827167.

 

  1. Hansen DK, Sidana S, Peres LC, Colin Leitzinger C, Shune L, Shrewsbury A, Gonzalez R, Sborov DW, Wagner C, Dima D, Hashmi H, Kocoglu MH, Atrash S, Simmons G, Kalariya N, Ferreri C, Afrough A, Kansagra A, Voorhees P, Baz R, Khouri J, Alsina M, McGuirk J, Locke FL, Patel KK. Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium. J Clin Oncol. 2023 Jan 9:JCO2201365. doi: 10.1200/JCO.22.01365. PMID: 36623248.

 

  1. Paul B, Liedtke M, Khouri J, Rifkin R, Gandhi MD, Kin A, Levy MY, Silbermann R, Cottini F, Sborov DW, Sandhu I, Villarreal L, Murphy M, Gu L, Chen A, Rajakumaraswamy N, Usmani SZ. A phase II multi-arm study of magrolimab combinations in patients with relapsed/refractory multiple myeloma. Future Oncol.2023 Jan;19(1):7-17. doi: 10.2217/fon-2022-0975. PMID: 36779512.

 

  1. Kumar SK, Callander NS, Adekola K, Anderson LD Jr, Baljevic M, Campagnaro E, Castillo JJ, Costello C, D'Angelo C, Devarakonda S, Elsedawy N, Garfall A, Godby K, Hillengass J, Holmberg L, Htut M, Huff CA, Hultcrantz M, Kang Y, Larson S, Lee HC, Liedtke M, Martin T, Omel J, Rosenberg A, Sborov D, Valent J, Berardi R, Kumar R. Systemic Light Chain Amyloidosis, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023 Jan;21(1):67-81. doi: 10.6004/jnccn.2023.0001. PMID: 36652935.

 

  1. Li J, Cho YK, Sborov DW, Phelps MA, Hofmeister CC, Poi MJ. Evaluating the Impacts of CYP3A4*1B and CYP3A5*3 Variations on Pharmacokinetic Behavior and Clinical Outcomes in Multiple Myeloma Patients With Autologous Stem Cell Transplant. Cancer Genomics Proteomics. 2023 Jan-Feb;20(1):9-17. doi: 10.21873/cgp.20360. PMID: 36581339; PMCID: PMC9806672.

 

  1. Tashi T, Yu J, Pandya S, Dieyi C, Scherber R, Parasuraman S. Trends in overall mortality among US veterans with primary myelofibrosis. BMC Cancer. 2023 Jan 14;23(1):48. doi: 10.1186/s12885-022-10495-6. PMID: 36641455; PMCID: PMC9840363.

 

  1. Abbott J, Corean J, Snyder AM, Florell SR, Miles R, Stephens D, Wada DA. Folliculocentric lymphocytic hypersensitivity reactions in CLL/SLL patients: A unique clinicopathologic entity amongst non-specific hypersensitivity reactions. Skin Health Dis. 2023 Jan 19;3(3):e208. doi: 10.1002/ski2.208. PMID: 37275409; PMCID: PMC10233078.

 

FEBRUARY

 

  1. Abou-Ismail MY, James PD, Flood VH, Connell NT. Beyond the guidelines: how we approach challenging scenarios in the diagnosis and management of von Willebrand disease. J Thromb Haemost. 2023 Feb;21(2):204-214. doi: 10.1016/j.jtha.2022.11.042. PMID: 36700502.

 

  1. Barnard ME, Meeks H, Jarboe EA, Albro J, Camp NJ, Doherty JA. Familial risk of epithelial ovarian cancer after accounting for gynaecological surgery: a population-based study. J Med Genet. 2023 Feb;60(2):119-127. doi: 10.1136/jmedgenet-2021-108402. PMCID: PMC9643667.

 

  1. Morra A, Schreurs MAC, Andrulis IL, Anton-Culver H, Augustinsson A, Beckmann MW, Behrens S, Bojesen SE, Bolla MK, Brauch H, Broeks A, Buys SS, Camp NJ, Castelao JE, Cessna MH, Chang-Claude J, Chung WK, Collaborators N, Colonna SV, Couch FJ, Cox A, Cross SS, Czene K, Daly MB, Dennis J, Devilee P, Dörk T, Dunning AM, Dwek M, Easton DF, Eccles DM, Eriksson M, Evans DG, Fasching PA, Fehm TN, Figueroa JD, Flyger H, Gabrielson M, Gago-Dominguez M, García-Closas M, García-Sáenz JA, Genkinger J, Grassmann F, Gündert M, Hahnen E, Haiman CA, Hamann U, Harrington PA, Hartikainen JM, Hoppe R, Hopper JL, Houlston RS, Howell A, Investigators A, Investigators K, Jakubowska A, Janni W, Jernström H, John EM, Johnson N, Jones ME, Kristensen VN, Kurian AW, Lambrechts D, Marchand LL, Lindblom A, Lubiński J, Lux MP, Mannermaa A, Mavroudis D, Mulligan AM, Muranen TA, Nevanlinna H, Nevelsteen I, Neven P, Newman WG, Obi N, Offit K, Olshan AF, Park-Simon TW, Patel AV, Peterlongo P, Phillips KA, Plaseska-Karanfilska D, Polley EC, Presneau N, Pylkäs K, Rack B, Radice P, Rashid MU, Rhenius V, Robson M, Romero A, Saloustros E, Sawyer EJ, Schmutzler RK, Schuetze S, Scott C, Shah M, Smichkoska S, Southey MC, Tapper WJ, Teras LR, Tollenaar RAEM, Tomczyk K, Tomlinson I, Troester MA, Vachon CM, van Veen EM, Wang Q, Wendt C, Wildiers H, Winqvist R, Ziogas A, Hall P, Pharoah PDP, Adank MA, Hollestelle A, Schmidt MK, Hooning MJ. Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival. Res Sq. 2023 Feb 13:rs.3.rs-2569372. doi: 10.21203/rs.3.rs-2569372/v1. PMCID: PMC9949248.

 

  1. Saad A, Loren A, Bolaños-Meade J, Chen G, Couriel D, Di Stasi A, El-Jawahri A, Elmariah H, Farag S, Gundabolu K, Gutman J, Ho V, Hoeg R, Horwitz M, Hsu J, Kassim A, Kharfan Dabaja M, Magenau J, Martin T, Mielcarek M, Moreira J, Nakamura R, Nieto Y, Ninos C, Oliai C, Patel S, Randolph B, Schroeder M, Tzachanis D, Varshavsky-Yanovsky AN, Vusirikala M, Algieri F, Pluchino LA. NCCN Guidelines® Insights: Hematopoietic Cell Transplantation, Version 3.2022. J Natl Compr Canc Netw. 2023 Feb;21(2):108-115. doi: 10.6004/jnccn.2023.0007. PMID: 36791762.

 

  1. Shouse G, Kaempf A, Gordon MJ, Artz AS, Yashar D, Sigmund AM, Smilnak G, Bair SM, Mian A, Fitzgerald LA, Bajwa A, Jaglowski SM, Bailey N, Shadman M, Patel K, Stephens DM, Kamdar M, Hill BT, Gauthier J, Karmali R, Nastoupil LJ, Kittai AS, Danilov AV. A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B cell lymphoma. Blood Adv. 2023 Feb 3:bloodadvances.2022009309. doi: 10.1182/bloodadvances.2022009309. PMID: 36735393.

 

  1. Fenlon JB, Hutten RJ, Johnson SB, Hu B, Shah H, Stephens DM, Maity A, Gaffney DK, Tao R. Evaluating patterns of care for early-stage low-grade follicular lymphoma in the rituximab era. Leuk Lymphoma. 2023 Feb;64(2):356-363. doi: 10.1080/10428194.2022.2148215. PMID: 36408967.

 

  1. Parsons MW, Rock C, Chipman JJ, Shah HR, Hu B, Stephens DM, Tao R, Tward JD, Gaffney DK. Secondary malignancies in non-Hodgkin lymphoma survivors: 40 years of follow-up assessed by treatment modality. Cancer Med. 2023 Feb;12(3):2624-2636. doi: 10.1002/cam4.5139. PMCID: PMC9939160.

 

  1. Murthy GSG, Kim S, Estrada-Merly N, Abid MB, Aljurf M, Assal A, Badar T, Badawy SM, Ballen K, Beitinjaneh A, Cerny J, Chhabra S, DeFilipp Z, Dholaria B, Perez MAD, Farhan S, Freytes CO, Gale RP, Ganguly S, Gupta V, Grunwald MR, Hamad N, Hildebrandt GC, Inamoto Y, Jain T, Jamy O, Juckett M, Kalaycio M, Krem MM, Lazarus HM, Litzow M, Munker R, Murthy HS, Nathan S, Nishihori T, Ortí G, Patel SS, Van der Poel M, Rizzieri DA, Savani BN, Seo S, Solh M, Verdonck LF, Wirk B, Yared JA, Nakamura R, Oran B, Scott B, Saber W. Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis. Haematologica. 2023 Feb 9. doi: 10.3324/haematol.2022.281958. PMID: 36779595.

 

  1. Ocier K, Abdelaziz S, Kim S, Rowe K, Snyder J, Deshmukh V, Newman M, Fraser A, Smith K, Porucznik C, Shoaf K, Stanford J, Lee C, Hashibe M. Contributions of cancer treatment, comorbidities, and obesity to aging-related disease risks among non-Hodgkin lymphoma survivors. Cancer Causes Control. 2023 Feb;34(2):171-180. doi: 10.1007/s10552-022-01652-0. PMID: 36414860.

 

MARCH

 

  1. Zafar A, Lim MY, Abou-Ismail MY. Eculizumab in the management of drug-induced thrombotic microangiopathy: A scoping review of the literature. Thromb Res. 2023 Mar 2;224:73-79. doi: 10.1016/j.thromres.2023.02.012. PMID: 36871347.

 

  1. Rodgers GM, Berndt M, Fonteno M, Gilreath JA. Prolonged Exposure to Caplacizumab as Rescue Therapy in Refractory Immune Thrombotic Thrombocytopenic Purpura. J Blood Med. 2023 Mar 2;14:209-211. doi: 10.2147/JBM.S395248. PMID: 36891167 PMCID: PMC9987240.

 

  1. Morra A, Mavaddat N, Muranen TA, Ahearn TU, Allen J, Andrulis IL, Auvinen P, Becher H, Behrens S, Blomqvist C, Bojesen SE, Bolla MK, Brauch H, Camp NJ, Carvalho S, Castelao JE, Cessna MH, Chang-Claude J, Chenevix-Trench G; NBCS Collaborators; Czene K, Decker B, Dennis J, Dörk T, Dorling L, Dunning AM, Ekici AB, Eriksson M, Evans DG, Fasching PA, Figueroa JD, Flyger H, Gago-Dominguez M, García-Closas M, Geurts-Giele WRR, Giles GG, Guénel P, Gündert M, Hahnen E, Hall P, Hamann U, Harrington PA, He W, Heikkilä P, Hooning MJ, Hoppe R, Howell A, Humphreys K; kConFab Investigators; Jakubowska A, Jung AY, Keeman R, Kristensen VN, Lubiński J, Mannermaa A, Manoochehri M, Manoukian S, Margolin S, Mavroudis D, Milne RL, Mulligan AM, Newman WG, Park-Simon TW, Peterlongo P, Pharoah PDP, Rhenius V, Saloustros E, Sawyer EJ, Schmutzler RK, Shah M, Spurdle AB, Tomlinson I, Truong T, van Veen EM, Vreeswijk MPG, Wang Q, Wendt C, Yang XR, Nevanlinna H, Devilee P, Easton DF, Schmidt MK. The impact of coding germline variants on contralateral breast cancer risk and survival.Am J Hum Genet. 2023 Mar 2;110(3):475-486. doi: 10.1016/j.ajhg.2023.02.003. PMID: 36827971.

 

  1. Mohyuddin GR, Kapur R, Costa L. Inclusion criteria of currently enrolling T-cell engaging trials in multiple myeloma: Should we be focusing on lines of prior therapy? Br J Haematol. 2023 Mar 14. doi: 10.1111/bjh.18755. PMID: 36916719.

 

  1. Ouchveridze E, Booth C, Mohyuddin GR. Subgroups and precision in myeloma. J Cancer Policy. 2023 Mar;35:100407. doi: 10.1016/j.jcpo.2023.100407. PMID: 36696948.

 

  1. Mohyuddin GR, Chakraborty R, Cliff ERS. The promise and harms of screening for plasma cell dyscrasias. Br J Haematol. 2023 Mar;200(6):704-707. doi: 10.1111/bjh.18634. PMID: 36626939.

 

  1. Sawalha L, Kelkar AH, Mohyuddin GR, Goodman AM, Gagelmann N, Al Hadidi S. Analysis of repeated roles in editorial boards at oncology focused journals. J Cancer Policy. 2023 Mar;35:100380. doi: 10.1016/j.jcpo.2022.100380. PMID: 36538988.

 

  1. Fang MC, Reynolds K, Tabada GH, Prasad PA, Sung SH, Parks AL, Garcia E, Portugal C, Fan D, Pai AP, Go AS. Assessment of the Risk of Venous Thromboembolism in Nonhospitalized Patients With COVID-19. JAMA Netw Open. 2023 Mar 1;6(3):e232338. doi: 10.1001/jamanetworkopen.2023.2338. PMID: 36912838; PMCID: PMC10011935.

 

  1. Boyiadzis M, Zhang MJ, Chen K, Abdel-Azim H, Abid MB, Aljurf M, Bacher U, Badar T, Badawy SM, Battiwalla M, Bejanyan N, Bhatt VR, Brown VI, Castillo P, Cerny J, Copelan EA, Craddock C, Dholaria B, Perez MAD, Ebens CL, Gale RP, Ganguly S, Gowda L, Grunwald MR, Hashmi S, Hildebrandt GC, Iqbal M, Jamy O, Kharfan-Dabaja MA, Khera N, Lazarus HM, Lin R, Modi D, Nathan S, Nishihori T, Patel SS, Pawarode A, Saber W, Sharma A, Solh M, Wagner JL, Wang T, Williams KM, Winestone LE, Wirk B, Zeidan A, Hourigan CS, Litzow M, Kebriaei P, de Lima M, Page K, Weisdorf DJ. Correction to: Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113AML patients. Leukemia. 2023 Mar 22. doi: 10.1038/s41375-023-01814-2. Erratum for: Leukemia. 2022 Oct 30;: PMID: 36949156.

 

  1. Song J, Kim SJ, Gollamudi J, Thiagarajan P, Prchal JT. Downregulated KLF2 in polycythemia vera and essential thrombocythemia induces prothrombotic gene expression. Blood Adv. 2023 Mar 14;7(5):712-717. doi: 10.1182/bloodadvances.2022008052. PMID: 36343116; PMCID: PMC9984957.

 

  1. Amaru R, Song J, Reading NS, Gordeuk VR, Prchal JT. "What We Know and What We Do Not Know about Evolutionary Genetic Adaptation to High Altitude Hypoxia in Andean Aymaras". Genes (Basel). 2023 Mar 3;14(3):640. doi: 10.3390/genes14030640. PMID: 36980912; PMCID: PMC10048644.

 

  1. Desai SH, Spinner MA, David K, Bachanova V, Goyal G, Kahl B, Dorritie K, Azzi J, Kenkre VP, Arai S, Chang C, Fusco B, Sumransub N, Hatic H, Saba R, Ibrahim U, Harris EI, Shah H, Murphy J, Ansell S, Jagadish D, Orellana-Noia V, Diefenbach C, Iyenger S, Rappazzo KC, Mishra R, Choi Y, Nowakowski GS, Advani RH, Micallef IN. Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed/refractory classic Hodgkin lymphoma. Am J Hematol. 2023 Mar;98(3):464-471. doi: 10.1002/ajh.26827. PMID: 36629030.

 

  1. Shah H, Jang H, Kim S, Halwani AS. A comprehensive SEER registry analysis of elderly patients with classical Hodgkin lymphoma based on treatment era and race. Br J Haematol. 2023 Mar;200(5):579-586. doi: 10.1111/bjh.18564. PMID: 36400571.

 

  1. Crudele F, Bianchi N, Terrazzan A, Ancona P, Frassoldati A, Gasparini P, D'Adamo AP, Papaioannou D, Garzon R, Wójcicka A, Gaj P, Jażdżewski K, Palatini J, Volinia S. Circular RNAs Could Encode Unique Proteins and Affect Cancer Pathways. Biology (Basel). 2023 Mar 24;12(4):493. doi: 10.3390/biology12040493. PMID: 37106694; PMCID: PMC10135897.

 

  1. Patel SS, Hong S, Rybicki L, Farlow S, Dabney J, Kalaycio M, Sobecks R, Majhail NS, Hamilton BK. A Pilot Trial of Patient-Reported Outcomes for Acute Graft-Versus-Host-Disease. Transplant Cell Ther. 2023 Mar 31:S2666-6367(23)01205-8. doi: 10.1016/j.jtct.2023.03.030. PMID: 37003415.

 

  1. Terpos E, Branagan AR, García-Sanz R, Trotman J, Greenberger LM, Stephens DM, Morel P, Kimby E, Frustaci AM, Hatjiharissi E, San-Miguel J, Dimopoulos MA, Treon SP, Leblond V. Report of consensus panel 5 from the 11th international workshop on Waldenstrom's macroglobulinemia on COVID-19 prophylaxis and management. Semin Hematol. 2023 Mar 29:S0037-1963(23)00024-0. doi: 10.1053/j.seminhematol.2023.03.004. PMID: 37099029; PMCID: PMC10050191.

 

APRIL

 

  1. Smith FL, Savage HP, Luo Z, Tipton CM, Lee FE, Apostol AC, Beaudin AE, Lopez DA, Jensen I, Keller S, Baumgarth N. B-1 plasma cells require non-cognate CD4 T cell help to generate a unique repertoire of natural IgM. J Exp Med. 2023 Apr 3;220(4):e20220195. doi: 10.1084/jem.20220195. PMID: 36811605. PMCID: PMC9960156.

 

  1. Cliff ERS, Reynolds G, Popat R, Teh BW, Kesselheim AS, Mohyuddin GR. Acknowledging Infection Risk in Bispecific Antibody Trials in the Treatment of Multiple Myeloma. J Clin Oncol. 2023 Apr 1;41(10):1949-1951. doi: 10.1200/JCO.22.02197. PMID: 36716411.

 

  1. Wagner CB, Boucher K, Nedved A, Micallef IN, Desai S, Hatic H, Goyal G, Zacholski E, Fegley A, Sigmund AM, Bond DA, Samuels C, Kamdar MK, Ba Aqeel S, Torka P, MacDougall K, Borogovac A, Rajeeve S, Sundaram S, Fedak K, Modi D, Travers E, Ayyappan S, Chilakamarri N, Brem EA, Ermann DA, Fitzgerald LA, Hu B, Stephens DM, Shah H. Effect of cumulative dose of brentuximab vedotin maintenance in relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of realworld outcomes. Haematologica. 2023 Apr 27. doi: 10.3324/haematol.2023.282780. PMID: 37102592.

 

  1. Vardell VA, Ermann DA, Fitzgerald LA, Shah HR, Hu B, Stephens DM. Influence of racial and ethnic identity on overall survival in patients with chronic lymphocytic leukemia. Am J Hematol. 2023 Apr 20. doi: 10.1002/ajh.26937. PMID: 37078687.

 

  1. Major A, Yu J, Shukla N, Che Y, Karrison TG, Treitman R, Kamdar M, Haverkos BM, Godfrey J, Babcook MA, Voorhees TJ, Carlson SG, Gaut D, Oliai C, Romancik JT, Winter AM, Hill BT, Bansal R, Villasboas JC, Nizamuddin IA, Karmali R, Fitzgerald LA, Stephens DM, Pophali PA, Trabolsi A, Schatz JH, Hu M, Bachanova V, Slade M, Singh N, Ahmed N, McGuirk JP, Bishop MR, Riedell PA, Kline J. Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: Outcomes from 15 U.S. institutions. Blood Adv. 2023 Apr 7:bloodadvances.2023010016. doi: 10.1182/bloodadvances.2023010016. PMID: 37026796.

 

  1. Balwani M, Bonkovsky HL, Levy C, Anderson KE, Bissell DM, Parker C, Takahashi F, Desnick RJ, Belongie K; Endeavor Investigators. Dersimelagon in Erythropoietic Protoporphyrias. N Engl J Med. 2023 Apr 13;388(15):1376-1385. doi: 10.1056/NEJMoa2208754. PMID: 37043653.

 

  1. Parks AL, Fang MC. Periprocedural Anticoagulation. Ann Intern Med. 2023 Apr;176(4):ITC49-ITC64. doi: 10.7326/AITC202304180. PMID: 37037035.

 

  1. Bumma N, Dhakal B, Fraser R, Estrada-Merly N, Anderson K, Freytes CO, Hildebrandt GC, Holmberg L, Krem MM, Lee C, Lekakis L, Lazarus HM, Mian H, Murthy HS, Nathan S, Nishihori T, Parrondo R, Patel SS, Solh M, Strouse C, Vesole DH, Kumar S, Qazilbash MH, Shah N, D'Souza A, Sidana S. Impact of bortezomib-based versus lenalidomide maintenance therapy on outcomes of patients with high-risk multiple myeloma. Cancer. 2023 Apr 6. doi: 10.1002/cncr.34778. PMID: 37021929.

 

  1. Kragesteen BK, Giladi A, David E, Halevi S, Geirsdóttir L, Lempke OM, Li B, Bapst AM, Xie K, Katzenelenbogen Y, Dahl SL, Sheban F, Gurevich-Shapiro A, Zada M, Phan TS, Avellino R, Wang SY, Barboy O, Shlomi-Loubaton S, Winning S, Markwerth PP, Dekalo S, Keren-Shaul H, Kedmi M, Sikora M, Fandrey J, Korneliussen TS, Prchal JT, Rosenzweig B, Yutkin V, Racimo F, Willerslev E, Gur C, Wenger RH, Amit I. The transcriptional and regulatory identity of erythropoietin producing cells. Nat Med. 2023 Apr 27. doi: 10.1038/s41591-023-02314-7. PMID: 37106166.

 

  1. Prchal JT, Reeves BN. EnvIRONment modifies polycythemia vera. Blood. 2023 Apr 27;141(17):2042-2044. doi: 10.1182/blood.2023020065. PMID: 37103951.

 

  1. Crees ZD, Rettig MP, Jayasinghe RG, Stockerl-Goldstein K, Larson SM, Arpad I, Milone GA, Martino M, Stiff P, Sborov D, Pereira D, Micallef I, Moreno-Jiménez G, Mikala G, Coronel MLP, Holtick U, Hiemenz J, Qazilbash MH, Hardy N, Latif T, García-Cadenas I, Vainstein-Haras A, Sorani E, Gliko-Kabir I, Goldstein I, Ickowicz D, Shemesh-Darvish L, Kadosh S, Gao F, Schroeder MA, Vij R, DiPersio JF. Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial. Nat Med. 2023 Apr;29(4):869-879. doi: 10.1038/s41591-023-02273-z. PMID: 37069359; PMCID: PMC10115633.

 

MAY

 

  1. Griffin R, Hanson HA, Avery BJ, Madsen MJ, Sborov DW, Camp NJ. Deep Transcriptome Profiling of Multiple Myeloma Using Quantitative Phenotypes. Cancer Epidemiol Biomarkers Prev. 2023 May 1;32(5):708-717. doi: 10.1158/1055-9965.EPI-22-0798. PMID: 36857768.

 

  1. Osman AEG, Mencia-Trinchant N, Saygin C, Moma L, Kim A, Housman G, Pozsgai M, Sinha E, Chandra P, Hassane DC, Sboner A, Sangani K, DiNardi N, Johnson C, Wallace SS, Jabri B, Luu H, Guzman ML, Desai P, Godley LA. Paired bone marrow and peripheral blood samples demonstrate lack of widespread dissemination of some CH clones. Blood Adv. 2023 May 9;7(9):1910-1914. doi: 10.1182/bloodadvances.2022008521. PMID: 36453641.

 

  1. Figlioli G, Billaud A, Ahearn TU, Antonenkova NN, Becher H, Beckmann MW, Behrens S, Benitez J, Bermisheva M, Blok MJ, Bogdanova NV, Bonanni B, Burwinkel B, Camp NJ, Campbell A, Castelao JE, Cessna MH, Chanock SJ; NBCS Collaborators; Czene K, Devilee P, Dörk T, Engel C, Eriksson M, Fasching PA, Figueroa JD, Gabrielson M, Gago-Dominguez M, García-Closas M, González-Neira A, Grassmann F, Guénel P, Gündert M, Hadjisavvas A, Hahnen E, Hall P, Hamann U, Harrington PA, He W, Hillemanns P, Hollestelle A, Hooning MJ, Hoppe R, Howell A, Humphreys K; KConFab Investigators; Jager A, Jakubowska A, Khusnutdinova EK, Ko YD, Kristensen VN, Lindblom A, Lissowska J, Lubiński J, Mannermaa A, Manoukian S, Margolin S, Mavroudis D, Newman WG, Obi N, Panayiotidis MI, Rashid MU, Rhenius V, Rookus MA, Saloustros E, Sawyer EJ, Schmutzler RK, Shah M, Sironen R, Southey MC, Suvanto M, Tollenaar RAEM, Tomlinson I, Truong T, van der Kolk LE, van Veen EM, Wappenschmidt B, Yang XR, Bolla MK, Dennis J, Dunning AM, Easton DF, Lush M, Michailidou K, Pharoah PDP, Wang Q, Adank MA, Schmidt MK, Andrulis IL, Chang-Claude J, Nevanlinna H, Chenevix-Trench G, Evans DG, Milne RL, Radice P, Peterlongo P. FANCM missense variants and breast cancer risk: a case-control association study of 75,156 European women. Eur J Hum Genet. 2023 May;31(5):578-587. doi: 10.1038/s41431-022-01257-w. PMID: 36707629; PMCID: PMC10172381.

 

  1. Muranen TA, Morra A, Khan S, Barnes DR, Bolla MK, Dennis J, Keeman R, Leslie G, Parsons MT, Wang Q, Ahearn TU, Aittomäki K, Andrulis IL, Arun BK, Behrens S, Bialkowska K, Bojesen SE, Camp NJ, Chang-Claude J, Czene K, Devilee P; HEBON investigators; Domchek SM, Dunning AM, Engel C, Evans DG, Gago-Dominguez M, García-Closas M, Gerdes AM, Glendon G, Guénel P, Hahnen E, Hamann U, Hanson H, Hooning MJ, Hoppe R, Izatt L, Jakubowska A, James PA, Kristensen VN, Lalloo F, Lindeman GJ, Mannermaa A, Margolin S, Neuhausen SL, Newman WG, Peterlongo P, Phillips KA, Pujana MA, Rantala J, Rønlund K, Saloustros E, Schmutzler RK, Schneeweiss A, Singer CF, Suvanto M, Tan YY, Teixeira MR, Thomassen M, Tischkowitz M, Tripathi V, Wappenschmidt B, Zhao E, Easton DF, Antoniou AC, Chenevix-Trench G, Pharoah PDP, Schmidt MK, Blomqvist C, Nevanlinna H. PREDICT validity for prognosis of breast cancer patients with pathogenic BRCA1/2 variants. NPJ Breast Cancer. 2023 May 12;9(1):37. doi: 10.1038/s41523-023-00546-x. PMID: 37173335; PMCID: PMC10182045.

 

  1. Clavero E, Sanchez-Maldonado JM, Macauda A, Ter Horst R, Sampaio-Marques B, Jurczyszyn A, Clay-Gilmour A, Stein A, Hildebrandt MAT, Weinhold N, Buda G, García-Sanz R, Tomczak W, Vogel U, Jerez A, Zawirska D, Wątek M, Hofmann JN, Landi S, Spinelli JJ, Butrym A, Kumar A, Martínez-López J, Galimberti S, Sarasquete ME, Subocz E, Iskierka-Jażdżewska E, Giles GG, Rybicka-Ramos M, Kruszewski M, Abildgaard N, Verdejo FG, Sánchez Rovira P, da Silva Filho MI, Kadar K, Razny M, Cozen W, Pelosini M, Jurado M, Bhatti P, Dudzinski M, Druzd-Sitek A, Orciuolo E, Li Y, Norman AD, Zaucha JM, Reis RM, Markiewicz M, Rodríguez Sevilla JJ, Andersen V, Jamroziak K, Hemminki K, Berndt SI, Rajkumar V, Mazur G, Kumar SK, Ludovico P, Nagler A, Chanock SJ, Dumontet C, Machiela MJ, Varkonyi J, Camp NJ, Ziv E, Vangsted AJ, Brown EE, Campa D, Vachon CM, Netea MG, Canzian F, Försti A, Sainz J. Polymorphisms within Autophagy-Related Genes as Susceptibility Biomarkers for Multiple Myeloma: A Meta-Analysis of Three Large Cohorts and Functional Characterization. Int J Mol Sci. 2023 May 9;24(10):8500. doi: 10.3390/ijms24108500. PMID: 37239846; PMCID: PMC10218542.

 

  1. Mercadal S, Gomez CA, Lee CJ, Couriel DR. Infectious complications following CAR-t cell therapy for B cell non-Hodgkin lymphoma: a single-center experience and review of the literature. Ann Hematol. 2023 May 29:1–7. doi: 10.1007/s00277-023-05131-7. PMID: 37246975; PMCID: PMC10225770.

 

  1. Goda C, Kolovich S, Rudich A, Karunasiri M, Kulkarni R, Rajgolikar G, Neidemire-Colley L, Singh S, Sircar A, Ranganathan P, Garzon R, Sehgal L, Dorrance AM. Epidermal growth factor-like 7 is a novel therapeutic target in mantle cell lymphoma. Exp Hematol. 2023 May 18:S0301-472X(23)00226-6. doi: 10.1016/j.exphem.2023.05.003. PMID: 37209901.

 

  1. Bindal P, Najjar M, Koehn K, Godara A, Sborov DW, McClune B, Julian K, Wagner C, Mohyuddin GR. Refractoriness to last line of therapy: how often is it mandated and reported? A systematic review of randomized myeloma trials. Leuk Lymphoma. 2023 May 11:1-4. doi: 10.1080/10428194.2023.2209682. Erratum in: Leuk Lymphoma. 2023 Jun 6;:1. PMID: 37170589.

 

  1. Mohyuddin GR, Goodman AM. Ineligible for transplant, but eligible for intensive quadruplet therapy-The value of 'add-on' trials for vulnerable patient populations. Eur J Cancer. 2023 May;185:164-166. doi: 10.1016/j.ejca.2023.02.026. PMID: 36996626.

 

  1. Chakraborty R, Al Hadidi S, Cliff ERS, Mohyuddin GR. Is aggressive treatment of smoldering myeloma the path to curing myeloma? Blood Adv. 2023 May 17:bloodadvances.2023009658. doi: 10.1182/bloodadvances.2023009658. PMID: 37196639.

 

  1. Davis JA, Sborov DW, Wesson W, Julian K, Abdallah AO, McGuirk JP, Ahmed N, Hashmi H. Efficacy and Safety of CD34+ Stem Cell Boost for Delayed Hematopoietic Recovery After BCMA Directed CAR T-cell Therapy. Transplant Cell Ther. 2023 May 22:S2666-6367(23)01295-2. doi: 10.1016/j.jtct.2023.05.012. PMID: 37225044.

 

  1. Mian A, Naqvi SAA, Ayaz A, Husnain M, Aljama MA, Mohyuddin GR, Koehn K, Mohan M, Bin Riaz I, Chakraborty R. Incidence of second primary malignancies in patients with multiple myeloma receiving anti-CD38 monoclonal antibodies: A systematic review and meta-analysis. Leuk Res. 2023 May 23;131:107324. doi: 10.1016/j.leukres.2023.107324. PMID: 37285641.

 

  1. Wang C, Ma A, McNutt ME, Hoyd R, Wheeler CE, Robinson LA, Chan CHF, Zakharia Y, Dodd RD, Ulrich CM, Hardikar S, Churchman ML, Tarhini AA, Singer EA, Ikeguchi AP, McCarter MD, Denko N, Tinoco G, Husain M, Jin N, Osman AEG, Eljilany I, Tan AC, Coleman SS, Denko L, Riedlinger G, Schneider BP, Spakowicz D, Ma Q. A bioinformatics tool for identifying intratumoral microbes from the ORIEN dataset.bioRxiv. 2023 May 24:2023.05.24.541982. doi: 10.1101/2023.05.24.541982. PMID: 37292990; PMCID: PMC10245834.

 

JUNE

 

  1. López DA, Otsuka KS, Apostol AC, Posada J, Sánchez-Arcila JC, Jensen KD, Beaudin AE. Both maternal IFNγ exposure and acute prenatal infection with Toxoplasma gondii activate fetal hematopoietic stem cells.EMBO J. 2023 Jun 1:e112693. doi: 10.15252/embj.2022112693. PMID: 37259639.

 

  1. McKnite A, Kim HS, Silva J, Christian JL. Lack of evidence that fibrillin1 regulates bone morphogenetic protein 4 activity in kidney or lung. Dev Dyn. 2023 Jun;252(6):761-769. doi: 10.1002/dvdy.578. PMID: 36825302.

 

  1. Trunk AD, Radwanski K, Heber C, Taylor A, Hsieh F, Harris A, Lee CJ, Phillips JD, Couriel DR. Impact of Cryopreservation on Extracorporeal Photopheresis (ECP)-Treated Leukocyte Subsets. Transplant Cell Ther. 2023 Jun;29(6):396.e1-396.e5. doi: 10.1016/j.jtct.2023.02.017. PMID: 36828177.

 

  1. Abdallah AO, Mahmoudjafari Z, Ahmed N, Cui W, Shune L, McGuirk J, Mohan M, Mohyuddin GR, Afrough A, Alkharabsheh O, Atrash S. Clinical efficacy of retreatment of daratumumab-based therapy (D2) in daratumumab-refractory multiple myeloma. Eur J Haematol. 2023 Jun;110(6):626-632. doi: 10.1111/ejh.13942. PMID: 36752328.

 

  1. Sharma N, Wayant C, Neupane K, Lenka J, Berger K, Goodman AM, Booth CM, Prasad V, Mohyuddin GR. Quality of content reporting on two major oncology media websites: OncLive and Targeted Oncology. J Cancer Policy. 2023 Jun;36:100411. doi: 10.1016/j.jcpo.2023.100411. PMID: 36773798.

 

  1. Tariq SM, Abdallah AO, Goodman A, Sborov D, Mohyuddin GR, Britt A. The Landscape of Currently Enrolling Maintenance Trials in Multiple Myeloma. Clin Hematol Int. 2023 Jun;5(2-3):170-176. doi: 10.1007/s44228-023-00044-8. PMID: 37133718.

 

  1. Miljkovic M, Seguin A, Jia X, Cox JE, Catrow JL, Bergonia H, Phillips JD, Stephens WZ, Ward DM. Loss of the mitochondrial protein Abcb10 results in altered arginine metabolism in MEL and K562 cells and nutrient stress signaling through ATF4. J Biol Chem. 2023 Jun 1:104877. doi: 10.1016/j.jbc.2023.104877. PMID: 37269954.

 

  1. Goyal G, Lau KW, Wang X, Davidoff AJ, Huntington SF, Jamy O, Calip G, Shah H, Stephens DM, Miksad R, Parikh RB, Takvorian S, Neparidze N, Seymour EK. The COVID-19 Pandemic and In-Person Visit Rate Disruptions Among Patients With Hematologic Neoplasms in the US in 2020 to 2021. JAMA Netw Open. 2023 Jun 1;6(6):e2316642. doi: 10.1001/jamanetworkopen.2023.16642. PMID: 37273206.

 

  1. Zurko JC, Nizamuddin I, Epperla N, David KA, Cohen JB, Moyo T, Ollila TA, Hess BT, Roy I, Ferdman R, Liu J, Chowdhury SM, Romancik JT, Bhansali RS, Harris EI, Sorrell M, Masel R, Kittai AS, Denlinger N, Sigmund AM, Fitzgerald LA, Galvez C, Ma S, Winter JN, Pro B, Gordon LI, Danilov AV, Stephens DM, Shah NN, Kenkre VP, Barta SK, Torka P, Shouse G, Karmali R. Peri-CAR-T practice patterns and survival predictors for all CAR-T patients and post-CAR-T failure in aggressive B-NHL. Blood Adv. 2023 Jun 27;7(12):2657-2669. doi: 10.1182/bloodadvances.2022008240. PMID: 36094847.

 

  1. Hentzen S, Meirson T, Koehn K, Goodman A, Chakraborty R, Sborov D, Rubinstein S, Mohyuddin GR. Attrition and withdrawal in multiple myeloma randomized controlled trials: A systematic review. Eur J Haematol. 2023 Jun 29. doi: 10.1111/ejh.14032. PMID: 37382045.
  2. Mohyuddin GR, Prasad V. Detecting Selection Bias in Observational Studies-When Interventions Work Too Fast. JAMA Intern Med. 2023 Jun 12. doi: 10.1001/jamainternmed.2023.2067. PMID: 37306983.

 

  1. Sengar M, Hopman WM, Mohyuddin GR, Goodman AM, Gyawali B, Mukherji D, Hammad N, Pramesh CS, Aggarwal A, Sullivan R, Booth CM. Randomised controlled trials evaluating anticancer therapies in haematological cancers: an overview of global research activity. Ecancermedicalscience. 2023 Jun 8;17:1558. doi: 10.3332/ecancer.2023.1558. PMID: 37396096; PMCID: PMC10310333.

 

  1. Wang C, Ma A, McNutt ME, Hoyd R, Wheeler CE, Robinson LA, Chan CHF, Zakharia Y, Dodd RD, Ulrich CM, Hardikar S, Churchman ML, Tarhini AA, Singer EA, Ikeguchi AP, McCarter MD, Denko N, Tinoco G, Husain M, Jin N, Osman AEG, Eljilany I, Tan AC, Coleman SS, Denko L, Riedlinger G, Schneider BP, Spakowicz D, Ma Q. A bioinformatics tool for identifying intratumoral microbes from the ORIEN dataset. bioRxiv [Preprint]. 2023 May 24:2023.05.24.541982. doi: 10.1101/2023.05.24.541982. PMID: 37292990; PMCID: PMC10245834.

 

  1. Wheeler CE, Coleman SS, Hoyd R, Denko L, Chan CHF, Churchman ML, Denko N, Dodd RD, Eljilany I, Hardikar S, Husain M, Ikeguchi AP, Jin N, Ma Q, McCarter MD, Osman AEG, Robinson LA, Singer EA, Tinoco G, Ulrich CM, Zakharia Y, Spakowicz D, Tarhini AA, Tan AC. The tumor microbiome as a predictor of outcomes in patients with metastatic melanoma treated with immune checkpoint inhibitors. bioRxiv. 2023 May 25:2023.05.24.542123. doi: 10.1101/2023.05.24.542123. PMID: 37292921; PMCID: PMC10245822.

 

  1. Litt HK, Parks AL, Velazquez AI. Blood Clots, or Thrombosis, in Patients With Cancer. JAMA Oncol. 2023 Jun 1;9(6):876. doi: 10.1001/jamaoncol.2022.6892. PMID: 37052914.

 

  1. de Jong CMM, de Wit K, Black SA, Gwozdz AM, Masias C, Parks AL, Robert-Ebadi H, Talerico R, Woller SC, Klok FA. Use of patient-reported outcome measures in patients with venous thromboembolism: communication from the ISTH SSC Subcommittee on Predictive and Diagnostic Variables in Thrombotic Disease. J Thromb Haemost. 2023 Jun 30:S1538-7836(23)00508-1. doi: 10.1016/j.jtha.2023.06.023. PMID: 37394119.

 

  1. Ragon BK, Shah MV, D'Souza A, Estrada-Merly N, Gowda L, George G, de Lima M, Hashmi S, Kharfan-Dabaja MA, Majhail NS, Banerjee R, Saad A, Hildebrandt GC, Mian H, Abid MB, Battiwalla M, Lekakis LJ, Patel SS, Murthy HS, Nieto Y, Strouse C, Badawy SM, Al Hadidi S, Dholaria B, Aljurf M, Vesole DH, Lee CH, Pawarode A, Gergis U, Miller KC, Holmberg LA, Afrough A, Solh M, Munshi PN, Nishihori T, Anderson LD, Wirk B, Kaur G, Qazilbash MH, Shah N, Kumar SK, Usmani SZ. Impact of second primary malignancy post-autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis. Blood Adv. 2023 Jun 27;7(12):2746-2757. doi: 10.1182/bloodadvances.2022009138. PMID: 36827681; PMCID: PMC10275699.

 

  1. Prchal JT, Semenza GL. On either side of homeostasis: EPAS1 gain and loss of function mutations. Haematologica. 2023 Jun 8. doi: 10.3324/haematol.2023.283285.  PMID: 37288511.

 

  1. Song J, Sundar KM, Horvathova M, Gangaraju R, Indrak K, Christensen RD, Genzor S, Lundby C, Divoky V, Ganz T, Prchal JT. Increased blood reactive oxygen species and hepcidin in obstructive sleep apnea precludes expected erythrocytosis. Am J Hematol. 2023 Jun 23. doi: 10.1002/ajh.26992. PMID: 37350302.

 

  1. Chavez JC, Foss FM, William BM, Brammer JE, Smith SM, Prica A, Zain JM, Tuscano JM, Shah H, Mehta-Shah N, Geethakumari PR, Wang BX, Zantinge S, Wang L, Zhang L, Boutrin A, Zhao W, Cheng L, Standifer N, Hewitt L, Enowtambong E, Shao W, Sharma S, Carlesso G, Moscow JA, Siu LL. Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma. Clin Cancer Res. 2023 May 15;29(10):1869-1878. doi: 10.1158/1078-0432.CCR-22-2955. PMID: 36826995.

 

  1. Johnson PC, Woyach JA, Ulrich A, Marcotte V, Nipp RD, Lage DE, Nelson AM, Newcomb RA, Rice J, Lavoie MW, Ritchie CS, Bartlett N, Stephens DM, Ding W, Owen C, Stone R, Ruppert AS, Mandrekar SJ, Byrd JC, El-Jawahri A, Le-Rademacher J, Rosko A. Geriatric assessment measures are predictive of outcomes in chronic lymphocytic leukemia. J Geriatr Oncol. 2023 Jun 15;14(6):101538. doi: 10.1016/j.jgo.2023.101538. PMID: 37329769.

 

  1. Siddiqi T, Maloney DG, Kenderian SS, Brander DM, Dorritie K, Soumerai J, Riedell PA, Shah NN, Nath R, Fakhri B, Stephens DM, Ma S, Feldman T, Solomon SR, Schuster SJ, Perna SK, Tuazon SA, Ou SS, Papp E, Peiser L, Chen Y, Wierda WG. Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study. Lancet. 2023 Jun 5:S0140-6736(23)01052-8. doi: 10.1016/S0140-6736(23)01052-8. PMID: 37295445.

 

NO SPECIFIC MONTH

 

  1. López DA, Beaudin AE. Isolation and Characterization of Fetal Liver Hematopoietic Stem Cells. Methods Mol Biol. 2023;2567:99-112. doi: 10.1007/978-1-0716-2679-5_7. PMID: 36255697.

Current Fellow’s Accomplishment Highlights

Chris Nevala-Plagemann, MD/ PGY5

Chris is a second-year fellow who works closely with his mentor, Dr. Garrido-Laguna, on a number of projects with a GI oncology focus. Chris has presented abstracts utilizing real-world data in collaboration with Flatiron Health at both ASCO GI 2019 and 2020, and most recently presented work at ASCO 2020 entitled “Real-world outcomes of patients with BRAF mutated mCRC treated in the United States.” He wrote a review article in Nature Reviews Clinical Oncology entitled “From State-Of-The-Art Treatments to Novel Therapies for Advanced-Stage Pancreatic Cancer” which was published in 2020. For his second year of fellowship, Chris has enrolled in the Masters of Science Clinical Investigation program and his future research will focus on evaluating at the impact of the gut microbiome on treatment outcomes in pancreatic cancer using stool samples collected from newly diagnosed PDAC patients. 

William “Bill” McKean, MD, PhD/ PGY5

Bill is a third-year fellow (who did an expedited residency through the MD/PhD PSTP program) who works in the lab of Dr. Jared Rutter. He is interested in neuro-oncology and plans to single board in medical oncology. His research involves understanding the metabolic dependencies of adult neural stem cells.  Specifically, he is interested in how pyruvate transport and lactate formation influence the differentiation of neurons and glial cells.  These findings will have direct implications toward treatment of aggressive tumors like glioblastoma and astrocytoma. They will also provide greater insight into cancer stem cells, resistant progenitor subpopulations within these neoplasms.

Charles Goodwin, MD PhD PGY6

Charles is a third-year fellow who works in the lab of Dr. Ryan O’Connell. Charles’ research specifically focuses on dysregulated metabolism in acute myeloid leukemia and metabolic interactions between leukemic blasts and the immune cells of the bone marrow tumor microenvironment.  He and his lab hope to identify therapeutic targets in metabolic pathways that directly kill leukemic blasts while simultaneously enhancing anti-leukemic immune responses in the bone marrow tumor microenvironment. They are particularly interested in fatty acid metabolism as a promising target.  

Eric Johnson, MD PGY6

Eric is a third-year and has been involved in a number of projects throughout fellowship, but more specifically he worked on a quality improvement-based project at the VA where he holds his continuity clinic. In order to help minimize skeletal-related events and pain complications from metastatic prostate cancer, he created a “bone-modifying agents’ guideline” utilizing the current status of the veteran’s prostate cancer and FRAX score. In doing so, he created an order set algorithm to guide physician’s choice of bone modifying agents. 

Lindsey Fitzgerald, MD PGY6

Lindsey is a third-year fellow who works closely with her mentors in the lymphoma group (Drs. Martha Glenn, Debbie Stephens, and Boyu Hu) on a number of ongoing research projects. Recently, she had an abstract accepted at ASCO 2020 in which she performed a multi-institutional retrospective analysis of elderly patients (age over 70) across 5 US academic institutions who were treated with commercial CAR-T cell therapy for relapsed/refractory DLBCL to evaluate efficacy and toxicity outcomes. For her work, she was awarded the "Conquer Cancer - Loxo Oncology Endowed Merit Award" for one of the best abstracts submitted by a trainee in oncology. 

Additionally, Lindsey was accepted into an externship in the National Cancer Institute's Cancer Therapy Evaluation Program (CTEP) near Washington, D.C. in October 2019. She served in the investigational drug branch (IDB) which oversees the early development and clinical application of novel therapeutics by collaborating with academia and industry. She reviewed letters of intent (LOIs) from top academic oncology investigators across the country, presented these LOIs to select committees with analysis of pros and cons for funding considerations, sat in on meetings with pharmaceutical companies, and learned the components of a successful LOI to make a clinical trial a reality. 

Former Fellow’s Accomplishment Highlights

Katie Kerrigan, DO (class of 2020)

Katie was our former chief fellow from 2019-2020 and stayed on as HCI faculty where she subspecializes in thoracic and head & neck oncology. Under the mentorship of Drs. Wallace Akeley and Shiven Patel, Katie performed a number of real-world research projects in collaboration with Flatiron Health. Two of her real-world NSCLC outcomes projects were presented at World Conference on Lung Cancer 2019 in Barcelona. Additionally, she performed a pilot study entitled “Prognostic Significance of Patient-Reported Outcomes in Cancer” which was published in the Journal of Oncology Practice in 2020. She was awarded the Joseph M. Quagliana award in September 2019 which provided financial support for her research. Katie plans to continue to study PROs in her practice and hopes to become a clinical investigator.

Benjamin Solomon, MD (class of 2019)

Ben was our former chief fellow from 2018-2019 and stayed on as HCI faculty where he sees general oncology patients at our satellite clinic in Jackson, WY and subspecializes in GI oncology.  Under the mentorship of Dr. Garrido-Laguna, Ben applied for and was accepted into the American Society of Clinical Oncology/American Association for Cancer Research Methods in Clinical Cancer Research Workshop, Vail, CO after his first year of fellowship.  During the Vail workshop, he developed and wrote a protocol entitled “A phase I trial to assess the safety and preliminary efficacy of FOLFOX combined with nivolumab and a TIGIT inhibitor (BMS-986207) in advanced gastrointestinal malignancies.” 

Justin Moser, MD (class of 2019)

Justin was very involved in clinical and real-world outcomes research with a specific emphasis on melanoma during his fellowship. He worked with numerous mentors including Drs. Grossman and Hu-Lieskovan from the melanoma group. His work has been both published and presented at a number of national (GI ASCO 2019) and international meetings (ESMO 2019), with his ESMO 2019 presentation entitled “Comparative-effectiveness of pembrolizumab versus nivolumab for patients with metastatic melanoma.” After graduation, Justin took an oncology position at HonorHealth in Scottsdale, AZ where he serves as an assistant professor and drug development scholar.   

David Gill, MD (class of 2019)

David was heavily involved in GU oncology research during his residency at the University of Utah and fellowship at HCI under the mentorship of Dr. Neeraj Agarwal. David has many publications in peer-reviewed journals discussing immunotherapy in RCC and in urothelial cancer, evaluating predictive biomarkers for responsiveness to VEGF inhibition in RCC, and in evaluating germline variants in prostate cancer which may be predictive to certain therapies. During his fellowship, he was awarded the Joseph M. Quagliana award in 2018. David single-boarded in medical oncology and graduated after two years of fellowship. He now practices at Intermountain Medical Center in Murray, UT and is their Director of GU Oncology.

Ami Patel, MD (class of 2017)

Ami Patel published two papers in 2016 on her research with Drs. Mike Deininger and Tom O'Hare. Her research focuses on the resistance of chronic myeloid leukemia to tyrosine kinase inhibitors (TKIs). She reported that inhibition of the STAT3 transcription factor blocks one mechanism of TKI resistance. This work published in Chem Med Chem highlights the potential therapeutic advantage of combinatorial treatment of CML. She published a first-author review on new strategies for therapy of BCR-ABL1-negative myeloproliferative neoplasms. This appeared in Clin Cancer Res in March of this year.

Sabarinath Venniyil Radhakrishnan, MBBS (class of 2016)

Sabarinath Radhakrishnan published a review article in the Br J Haematol on chimeric antigen receptor (CAR) therapy for multiple myeloma. Sabarinath's research with Drs. D. Atanackovic and T. Leutkens focuses on generating new CAR T cells therapies for multiple myeloma therapy. He is making excellent progress on a new antigen for CAR therapy.

Hematology Bi-Annual Report 2017

Read the Report

Why Utah?

Related Links

Graduate Medical Education Office
Oncology Division